Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Apollomics Inc WT (APLMW)

Apollomics Inc WT (APLMW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Apollomics Inc. Announces $2.0 Million Bridge Financing GlobeNewswire - Wed Apr 1, 6:00AM CDT

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible...

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics Reports First Half 2025 Financial Results GlobeNewswire - Mon Dec 22, 2025

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple...

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics Announces Settlement of Cayman Litigation GlobeNewswire - Wed Nov 19, 2025

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement”...

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics Announces Changes to its Board of Directors and Composition of Committees GlobeNewswire - Mon Nov 17, 2025

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today...

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation GlobeNewswire - Wed Oct 15, 2025

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing...

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics, Inc. Company Operational Continuity Update GlobeNewswire - Mon Oct 13, 2025

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics...

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Nasdaq Halts Apollomics Inc., Ltd. GlobeNewswire - Wed Sep 17, 2025

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market ® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional...

NDAQ : 84.58 (+1.71%)
APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress GlobeNewswire - Thu Apr 3, 2025

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib GlobeNewswire - Mon Mar 31, 2025

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia GlobeNewswire - Fri Dec 20, 2024

APLM : 14.20 (+4.41%)
APLMW : 0.0156 (+12.23%)

Barchart Exclusives

Michael Burry is Loading Up on JD.com Stock. Should You? Barchart - 15 minutes ago
Michael Burry just added JD.com stock to his portfolio, calling recent weakness "an attractive entry point." Here's what the numbers say and whether you should follow his move. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.